BC Advantage - 2017 Issue 5

Intravenous Form of Sensipar® Has Been Approved by the FDA

Parsabiv™ (etelcalcetide), an IV formulation similar to the oral calcimimetic Sensipar® (cinicalset), was recently approved by the U.S. Food and Drug Administration to treat secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. This is the first medication that has been approved to treat secondary hyperparathyroidism in 12 years.Calcimimetic drugs like Sensipar® and Parsabiv™ work to lower the parathyroid hormone (PTH) level, which controls calcium, phosphorus, and vitamin D in the blood. This in turn helps regulate bone growth. High PTH is common in patients with chronic kidney disease, and many of the patients on dialysis...

To read the full article, sign in and subscribe to BC Advantage.

Access to this feature is available in the following products:
  • BC Advantage, 30+ CEUs & Webinars

demo
request yours today
 subscribe
start today
 newsletter
free subscription

Thank you for choosing Find-A-Code, please Sign In to remove ads.